MA46523A - Procédés de criblage de modulateurs d'une activité biologique de type gdf15 - Google Patents

Procédés de criblage de modulateurs d'une activité biologique de type gdf15

Info

Publication number
MA46523A
MA46523A MA046523A MA46523A MA46523A MA 46523 A MA46523 A MA 46523A MA 046523 A MA046523 A MA 046523A MA 46523 A MA46523 A MA 46523A MA 46523 A MA46523 A MA 46523A
Authority
MA
Morocco
Prior art keywords
gdf15
processes
biological activity
type biological
screening modulators
Prior art date
Application number
MA046523A
Other languages
English (en)
Inventor
Anthony Armstrong
Stephen Beck
Jose Antonio Chavez
Chen-Ni Chin
Thai Dinh
Jennifer Furman
Matt Husovsky
Xiefan Lin-Schmidt
Shannon Mullican
Shamina Rangwala
Vicki South
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA46523A publication Critical patent/MA46523A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
MA046523A 2016-10-12 2017-10-11 Procédés de criblage de modulateurs d'une activité biologique de type gdf15 MA46523A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662407046P 2016-10-12 2016-10-12

Publications (1)

Publication Number Publication Date
MA46523A true MA46523A (fr) 2019-08-21

Family

ID=60186389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046523A MA46523A (fr) 2016-10-12 2017-10-11 Procédés de criblage de modulateurs d'une activité biologique de type gdf15

Country Status (9)

Country Link
US (1) US20190234935A1 (fr)
EP (1) EP3526346A1 (fr)
JP (1) JP2020503842A (fr)
KR (1) KR20190059312A (fr)
AU (1) AU2017342028A1 (fr)
CA (1) CA3038846A1 (fr)
IL (1) IL265808A (fr)
MA (1) MA46523A (fr)
WO (1) WO2018071493A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815793B (zh) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
JP2021533743A (ja) 2018-08-10 2021-12-09 ノバルティス アーゲー Ｇｆｒａｌ細胞外ドメイン及び使用方法
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
CA3178994A1 (fr) 2020-05-19 2021-11-25 Iyassu Sebhat Activateurs d'ampk
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
WO2023154953A1 (fr) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes
WO2024155160A1 (fr) * 2023-01-20 2024-07-25 한국과학기술원 Oligomères antisens ciblant le gfral et leur utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU669489B2 (en) 1991-09-18 1996-06-13 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
PT665897E (pt) 1992-10-01 2003-11-28 Trustees Of Columbia U In The Bibliotecas quimicas combinatorias complexas codificadas com etiquetas
JPH09508353A (ja) 1993-11-02 1997-08-26 アフィマックス テクノロジーズ ナムローゼ フェンノートシャップ 分子多様性の合成及びスクリーニング
AU691296B2 (en) 1994-05-06 1998-05-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6010861A (en) 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
PT2929891T (pt) * 2004-04-13 2020-04-08 St Vincents Hospital Sydney Ltd Método para modulação do apetite
CA2832581C (fr) * 2011-04-08 2022-08-23 Yumei Xiong Methode de traitement ou d'amelioration de troubles metaboliques a l'aide du facteur 15 de differenciation de croissance (gdf-15)
WO2013113008A1 (fr) * 2012-01-26 2013-08-01 Amgen Inc. Polypeptides du facteur de croissance et de différenciation 15 (gdf-15)
PT3122775T (pt) * 2014-03-26 2019-12-26 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
JP6910800B2 (ja) * 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
US20170306008A1 (en) * 2014-09-25 2017-10-26 Aveo Pharmaceuticals, Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
EP3423094A4 (fr) * 2016-02-29 2019-11-06 Eli Lilly and Company Traitements impliquant le récepteur gfral
TWI815793B (zh) * 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法

Also Published As

Publication number Publication date
AU2017342028A1 (en) 2019-04-11
JP2020503842A (ja) 2020-02-06
US20190234935A1 (en) 2019-08-01
WO2018071493A1 (fr) 2018-04-19
KR20190059312A (ko) 2019-05-30
EP3526346A1 (fr) 2019-08-21
IL265808A (en) 2019-06-30
CA3038846A1 (fr) 2018-04-19

Similar Documents

Publication Publication Date Title
MA46523A (fr) Procédés de criblage de modulateurs d'une activité biologique de type gdf15
MA56008A (fr) Composés et compositions pour traiter des états associés à une activité de nlrp
MA46278A (fr) Molécules de liaison qui modulent une activité biologique exprimée par une cellule
FR24C1022I1 (fr) Modulation d'activité du complément
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA44734A (fr) Composés et compositions destinés au traitement d'états associés à une activité de nlrp
GB202001657D0 (en) Prediction of adverse drug reactions
MA42269A (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
MA43756A (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
BR112016030690A2 (pt) moduladores do receptor de arila e métodos de fabricar e usar os mesmos
CL2015000717A1 (es) Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c.
MA49153A (fr) Éléments régulateurs à haute activité
FR3020343B1 (fr) Ensemble pour aeronef comprenant une structure primaire de mat d'accrochage constituee par trois elements independants
MA41169A (fr) Composés antibactériens à large spectre d'activité
DK3463351T3 (da) Behandling til parkinsons sygdom
GB201610425D0 (en) Analysis of images of biological material
MA41198A (fr) Essais d'activité enzymatique pour i2s
MA53014A (fr) Composés améliorant l'activité du protéasome
MA50838A (fr) Procédés de production de matieres végétales ensilées à l'aide de megasphaera elsdenii
FR3046471B1 (fr) Methode de calibration d'une interface neuronale directe par regression multivoie penalisee
DK3819007T3 (da) Doseringsplan for anti-bcma-midler
EP3623369C0 (fr) Nouveaux composés de morpholinyle amine pour le traitement des maladies auto-immunes